{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:22:22Z","timestamp":1794666142047,"version":"4.9.1"},"reference-count":100,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>High-dose methotrexate (HDMTX) is a cornerstone therapeutic regimen for hematological malignancies; however, delayed elimination remains a significant clinical challenge. Currently, no standardized definition for delayed elimination exists. This scoping review aims to identify and characterize methotrexate elimination threshold variability and its implication on clinical data interpretation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>A literature search was conducted using PubMed, Scopus, and the Cochrane database to identify studies published in English from the 1960s to February 2025. All study types reporting delayed elimination thresholds for high-dose methotrexate in adult patients with hematological malignancies were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result:<\/jats:title>\n                    <jats:p>Twenty-three studies meeting the inclusion criteria were charted and summarized. The most frequently reported thresholds were 10 \u00b5mol\/L at 24 hours (42%), 1 \u00b5mol\/L at 48 hours (44%), and 0.1 \u00b5mol\/L at 72 hours (55%). The threshold values varied widely at 24, 48, and 72 hours by 750-, 100-, and 3-folds, respectively. For most of the studies (87%), time measurement was initiated at the start of infusion. Majority of studies (81%) used immunoassays to quantify methotrexate, whereas 19% used liquid chromatography, with no significant difference in concentration thresholds observed between assay types.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Significant variability exists in the thresholds used to define delayed HDMTX elimination, particularly at 48 hours, with the differences not explained by assay method. These inconsistencies affect clinical decisions, including toxicity predictions and rescue therapy implementation. Although standardization is needed to improve comparability, threshold definitions should also reflect population-specific pharmacokinetics and toxicity profiles to support more precise HDMTX monitoring and outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001401","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T21:02:49Z","timestamp":1763499769000},"page":"432-442","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Delayed Elimination Concentrations of High-Dose Methotrexate in Adults With Hematological Malignancies: To Standardize or Not? A Scoping Review"],"prefix":"10.1097","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6296-4090","authenticated-orcid":false,"given":"Fauziah","family":"T","sequence":"first","affiliation":[{"name":"Centre for Quality Management of Medicines, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1721-6778","authenticated-orcid":false,"given":"Ai Sim","family":"Goh","sequence":"additional","affiliation":[{"name":"Hospital Pulau Pinang, Pulau Pinang, Malaysia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2509-4213","authenticated-orcid":false,"given":"Noraida","family":"Mohamed Shah","sequence":"additional","affiliation":[{"name":"Centre for Quality Management of Medicines, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0592-0645","authenticated-orcid":false,"given":"Mohd","family":"Makmor-Bakry","sequence":"additional","affiliation":[{"name":"Centre for Quality Management of Medicines, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6243-6975","authenticated-orcid":false,"given":"Shamin","family":"Mohd Saffian","sequence":"additional","affiliation":[{"name":"Centre for Quality Management of Medicines, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"R1-20261114","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0305-7372(77)80007-8","article-title":"Methotrexate: clinical pharmacology, current status and therapeutic guidelines","volume":"4","author":"Bleyer","year":"1977","journal-title":"Cancer Treat Rev."},{"key":"R2-20261114","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I","article-title":"The clinical pharmacology of methotrexate: new applications of an old drug","volume":"41","author":"Bleyer","year":"1978","journal-title":"Cancer"},{"key":"R3-20261114","first-page":"1429","article-title":"Methylaminopterin (Methotrexate) in the treatment of psoriasis. A review [in Danish]","volume":"131","author":"Nyfors","year":"1969","journal-title":"Ugeskr Laeger"},{"key":"R4-20261114","first-page":"25","article-title":"Longterm methotrexate therapy in rheumatoid arthritis: a review","volume":"12","author":"Kremer","year":"1985","journal-title":"J Rheumatol."},{"key":"R5-20261114","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/00006254-199007000-00001","article-title":"Cervical ectopic pregnancy: review of the literature and report of a case treated by single-dose methotrexate therapy","volume":"45","author":"Yankowitz","year":"1990","journal-title":"Obstet Gynecol Surv."},{"key":"R6-20261114","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1002\/1097-0142(197712)40:6<2823::AID-CNCR2820400612>3.0.CO;2-2","article-title":"High dose methotrexate with citrovorum factor in adult resistant lymphoma","volume":"40","author":"Turman","year":"1977","journal-title":"Cancer"},{"key":"R7-20261114","first-page":"381","article-title":"Clinical experiences with high-dose methotrexate [in German]","volume":"96","author":"Geissler","year":"1984","journal-title":"Wien Klin Wochenschr"},{"key":"R8-20261114","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.1987.5.12.2017","article-title":"High-dose methotrexate: a critical reappraisal","volume":"5","author":"Ackland","year":"1987","journal-title":"J Clin Oncol."},{"key":"R9-20261114","first-page":"39","article-title":"Central nervous system (CNS) involvement in acute leukemia and lymphoma: indications for CNS assessment and advice for diagnostic strategy","volume":"36","author":"Ringhoffer","year":"2012","journal-title":"J Lab Med."},{"key":"R10-20261114","doi-asserted-by":"crossref","first-page":"20","DOI":"10.21037\/aol-20-54","article-title":"Overcoming the blood-brain barrier in primary central nervous system lymphoma: a review on new strategies to solve an old problem","volume":"5","author":"Calimeri","year":"2021","journal-title":"Ann Lymphoma"},{"key":"R11-20261114","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1182\/blood.V128.22.928.928","article-title":"Primary central nervous system lymphoma and the blood-brain barrier","volume":"128","author":"Doolittle","year":"2016","journal-title":"Blood"},{"key":"R12-20261114","doi-asserted-by":"crossref","first-page":"219","DOI":"10.4137\/CMO.S7752","article-title":"Current and emerging pharmacotherapies for primary CNS lymphoma","volume":"6","author":"Prodduturi","year":"2012","journal-title":"Clin Med Insights Oncol."},{"key":"R13-20261114","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41392-024-01941-x","article-title":"Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: a phase 2 study","volume":"9","author":"Zeng","year":"2024","journal-title":"Signal Transduct Target Ther."},{"key":"R14-20261114","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1111\/bjh.19659","article-title":"Combination of rituximab and methotrexate followed by rituximab and cytarabine in elderly patients with primary central nervous system lymphoma","volume":"205","author":"Yi","year":"2024","journal-title":"Br J Haematol."},{"key":"R15-20261114","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-024-01606-w","article-title":"Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB\/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients","volume":"17","author":"Alcantara","year":"2024","journal-title":"J Hematol Oncol."},{"key":"R16-20261114","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11910-024-01389-0","article-title":"Advances in primary central nervous system lymphoma","volume":"25","author":"Therkelsen","year":"2024","journal-title":"Curr Neurol Neurosci Rep."},{"key":"R17-20261114","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3892\/mco.2022.2592","article-title":"Outcomes of high-dose methotrexate for CNS prophylaxis in diffuse large B-cell lymphoma with an intermediate or high CNS-International Prognostic Index: a single-center retrospective cohort study","volume":"17","author":"Al-Mansour","year":"2022","journal-title":"Mol Clin Oncol."},{"key":"R18-20261114","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41408-021-00506-3","article-title":"Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse","volume":"11","author":"Bobillo","year":"2021","journal-title":"Blood Cancer J."},{"key":"R19-20261114","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/FTD.0000000000000085","article-title":"Using fluorescence polarization immunoassay for determination of erythrocyte methotrexate polyglutamates, a quick and easy test?","volume":"36","author":"den Boer","year":"2014","journal-title":"Ther Drug Monit."},{"key":"R20-20261114","first-page":"1536","article-title":"Influence of folylpolyglutamate synthetase genetic polymorphism on treatment of methotrexate in acute lymphocytic leukemia patients","volume":"50","author":"Huang","year":"2015","journal-title":"Chin Pharm J."},{"key":"R21-20261114","doi-asserted-by":"crossref","first-page":"e70516","DOI":"10.1002\/cam4.70516","article-title":"Impact of methotrexate and 7-hydroxymethotrexate exposure on renal toxicity in pediatric Non-Hodgkin lymphoma","volume":"14","author":"Bing","year":"2025","journal-title":"Cancer Med."},{"key":"R22-20261114","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1200\/JCO.1983.1.3.208","article-title":"Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine","volume":"1","author":"Abelson","year":"1983","journal-title":"J Clin Oncol."},{"key":"R23-20261114","first-page":"207","article-title":"Transient acute hepatotoxicity of high-dose methotrexate therapy during childhood","volume":"5","author":"Weber","year":"1987","journal-title":"NCI Monogr."},{"key":"R24-20261114","first-page":"e29518","article-title":"Overview of methotrexate toxicity: a comprehensive literature review","volume":"14","author":"Hamed","year":"2022","journal-title":"Cureus"},{"key":"R25-20261114","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/MPH.0000000000000696","article-title":"Using a bedside algorithm to individually dose high-dose methotrexate for patients at risk for toxicity","volume":"39","author":"Foster","year":"2017","journal-title":"J Pediatr Hematol Oncol."},{"key":"R26-20261114","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00280-021-04305-2","article-title":"A minimal physiologically based pharmacokinetic model for high-dose methotrexate","volume":"88","author":"Pesenti","year":"2021","journal-title":"Cancer Chemother Pharmacol."},{"key":"R27-20261114","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1365-2125.2011.04084.x","article-title":"Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate","volume":"73","author":"Joerger","year":"2012","journal-title":"Br J Clin Pharmacol."},{"key":"R28-20261114","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s00280-004-0797-y","article-title":"Late-onset delayed excretion of methotrexate","volume":"54","author":"Pauley","year":"2004","journal-title":"Cancer Chemother Pharmacol."},{"key":"R29-20261114","doi-asserted-by":"crossref","first-page":"e41363","DOI":"10.1097\/MD.0000000000041363","article-title":"High-dose methotrexate-based chemotherapy for induction remission of newly diagnosed primary CNS lymphoma: a systematic review and meta-analysis","volume":"104","author":"Shi","year":"2025","journal-title":"Medicine (Baltimore)"},{"key":"R30-20261114","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0378-4274(95)03279-7","article-title":"Defining thresholds in occupational and environmental toxicology","volume":"77","author":"Aldridge","year":"1995","journal-title":"Toxicol Lett."},{"key":"R31-20261114","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF00262416","article-title":"Pharmacokinetic monitoring of high-dose methotrexate","volume":"3","author":"Evans","year":"1979","journal-title":"Cancer Chemother Pharmacol."},{"key":"R32-20261114","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJM197709222971203","article-title":"Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity","volume":"297","author":"Stoller","year":"1977","journal-title":"N Engl J Med."},{"key":"R33-20261114","doi-asserted-by":"crossref","first-page":"e068427","DOI":"10.1136\/bmjopen-2022-068427","article-title":"Growth patterns in childhood and adolescence and adult body composition: a pooled analysis of birth cohort studies from five low and middle-income countries (COHORTS collaboration)","volume":"13","author":"Poveda","year":"2023","journal-title":"BMJ Open"},{"key":"R35-20261114","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00228-023-03579-0","article-title":"Factors influencing methotrexate pharmacokinetics highlight the need for individualized dose adjustment: a systematic review","volume":"80","author":"Yang","year":"2024","journal-title":"Eur J Clin Pharmacol."},{"key":"R36-20261114","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med."},{"key":"R37-20261114","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jclinepi.2020.03.016","article-title":"Reporting scoping reviews-PRISMA ScR extension","volume":"123","author":"McGowan","year":"2020","journal-title":"J Clin Epidemiol."},{"key":"R38-20261114","first-page":"3","article-title":"Effect of serum albumin level on high-dose methotrexate induced toxicities in acute lymphoblastic leukemia patients","volume":"17","author":"Mirza","year":"2023","journal-title":"Int J Health Sci (Qassim)."},{"key":"R39-20261114","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2217\/pgs-2022-0169","article-title":"Correlation between methylation level of the SLC19A1 promoter region and methotrexate metabolism in adult acute lymphoblastic leukemia","volume":"24","author":"Huang","year":"2023","journal-title":"Pharmacogenomics"},{"key":"R40-20261114","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/1060028019870445","article-title":"A previously unknown drug-drug interaction is suspected in delayed elimination of plasma methotrexate in high-dose methotrexate therapy","volume":"54","author":"Ishizaki","year":"2020","journal-title":"Ann Pharmacother."},{"key":"R41-20261114","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2125.2008.03303.x","article-title":"Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy","volume":"67","author":"Suzuki","year":"2009","journal-title":"Br J Clin Pharmacol."},{"key":"R42-20261114","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1111\/jcpt.13425","article-title":"Delayed methotrexate elimination in a patient with primary central nervous system lymphoma: a case report","volume":"46","author":"Urata","year":"2021","journal-title":"J Clin Pharm Ther."},{"key":"R43-20261114","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1080\/1042819021000032953","article-title":"Carboxypeptidase-G2 rescue in cancer patients with delayed methotrexate elimination after high-dose methotrexate therapy","volume":"43","author":"Krause","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"R44-20261114","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1177\/10781552211052564","article-title":"Effective elimination of high-dose methotrexate by repeated hemodiafiltration and high-flux hemodialysis in patients with acute kidney injury","volume":"28","author":"Sakran","year":"2022","journal-title":"J Oncol Pharm Pract."},{"key":"R45-20261114","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3109\/10428194.2013.789506","article-title":"Genetic polymorphisms predicting methotrexate blood levels and toxicity in adult Non-Hodgkin lymphoma","volume":"55","author":"Avivi","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"R46-20261114","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/annonc\/mdi075","article-title":"High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma","volume":"16","author":"Jahnke","year":"2005","journal-title":"Ann Oncol."},{"key":"R47-20261114","doi-asserted-by":"crossref","first-page":"7599","DOI":"10.1007\/s13277-015-3403-5","article-title":"ABCB1 polymorphisms correlate with susceptibility to adult acute leukemia and response to high-dose methotrexate","volume":"36","author":"Ma","year":"2015","journal-title":"Tumour Biol."},{"key":"R48-20261114","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1186\/s12885-021-08443-x","article-title":"Evaluation of body-surface-area adjusted dosing of high-dose methotrexate by population pharmacokinetics in a large cohort of cancer patients","volume":"21","author":"Arshad","year":"2021","journal-title":"BMC Cancer"},{"key":"R49-20261114","doi-asserted-by":"crossref","first-page":"bcr2014203530","DOI":"10.1136\/bcr-2014-203530","article-title":"The utility of online haemodiafiltration in methotrexate poisoning","volume":"2014","author":"Abdelsalam","year":"2014","journal-title":"BMJ Case Rep."},{"key":"R50-20261114","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/FTD.0000000000000813","article-title":"Body surface area dosing of high-dose methotrexate should be reconsidered, particularly in overweight, adult patients","volume":"43","author":"Gallais","year":"2021","journal-title":"Ther Drug Monit."},{"key":"R51-20261114","doi-asserted-by":"crossref","first-page":"817673","DOI":"10.3389\/fphar.2022.817673","article-title":"Evaluation and application of population pharmacokinetic models for identifying delayed methotrexate elimination in patients with primary central nervous system lymphoma","volume":"13","author":"Mao","year":"2022","journal-title":"Front Pharmacol."},{"key":"R52-20261114","doi-asserted-by":"crossref","first-page":"7719","DOI":"10.12659\/MSM.912999","article-title":"Renal function and plasma methotrexate concentrations predict toxicities in adults receiving high-dose methotrexate","volume":"24","author":"Yang","year":"2018","journal-title":"Med Sci Monit."},{"key":"R53-20261114","doi-asserted-by":"crossref","first-page":"e5789","DOI":"10.1002\/bmc.5789","article-title":"An ultrahigh-performance liquid chromatography-tandem mass spectrometry method for quantification of methotrexate and 7-hydroxy-methotrexate and application for therapeutic drug monitoring in patients with central nervous system lymphoma","volume":"38","author":"Huo","year":"2024","journal-title":"Biomed Chromatogr."},{"key":"R54-20261114","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00280-020-04058-4","article-title":"Pharmacokinetics and pharmacogenetics of high-dose methotrexate in Chinese adult patients with non-Hodgkin lymphoma: a population analysis","volume":"85","author":"Yang","year":"2020","journal-title":"Cancer Chemother Pharmacol."},{"key":"R55-20261114","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/mpo.2950020313","article-title":"High dose methotrexate therapy of solid tumors: observations relating to clinical toxicity","volume":"2","author":"Isacoff","year":"1976","journal-title":"Med Pediatr Oncol."},{"key":"R56-20261114","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/ijc.2910380603","article-title":"Pharmacokinetics of methotrexate and its 7-OH metabolite in cancer patients treated with different high-methotrexate dosage regimens","volume":"38","author":"Ei-Yazigi","year":"1986","journal-title":"Int J Cancer"},{"key":"R57-20261114","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1080\/02841860510029770","article-title":"High dose methotrexate in adult patients with osteosarcoma: clinical and pharmacokinetic results","volume":"44","author":"Comandone","year":"2005","journal-title":"Acta Oncol."},{"key":"R58-20261114","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1634\/theoncologist.2017-0243","article-title":"Consensus guideline for use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearance","volume":"23","author":"Ramsey","year":"2018","journal-title":"Oncologist"},{"key":"R59-20261114","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00432-024-05945-6","article-title":"A European consensus recommendation on the management of delayed methotrexate elimination: supportive measures, leucovorin rescue and glucarpidase treatment","volume":"150","author":"Bielack","year":"2024","journal-title":"J Cancer Res Clin Oncol."},{"key":"R60-20261114","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1111\/bcp.15134","article-title":"Medication therapy of high\u2010dose methotrexate: an evidence\u2010based practice guideline of the division of therapeutic drug monitoring, Chinese pharmacological society","volume":"88","author":"Song","year":"2022","journal-title":"Br J Clin Pharmacol."},{"key":"R61-20261114","first-page":"988","article-title":"Massive dose methotrexate with citrovorum factor rescue: MTX-pharmacokinetics, excretion pattern, and techniques for safety administration (author's transl) [in Japanese]","volume":"14","author":"Sasaki","year":"1979","journal-title":"Nihon Gan Chiryo Gakkai Shi"},{"key":"R62-20261114","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/FTD.0000000000000434","article-title":"Evaluation of the novel methotrexate architect chemiluminescent immunoassay: clinical impact on pharmacokinetic monitoring","volume":"39","author":"Aumente","year":"2017","journal-title":"Ther Drug Monit."},{"key":"R63-20261114","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1134\/S1061934820100111","article-title":"Development and validation of a high-performance liquid chromatography\u2013tandem mass spectrometry method for methotrexate quantitation in human serum","volume":"75","author":"Razali","year":"2020","journal-title":"J Anal Chem."},{"key":"R64-20261114","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jpha.2019.06.001","article-title":"Analytical methodologies for determination of methotrexate and its metabolites in pharmaceutical, biological and environmental samples","volume":"9","author":"Karami","year":"2019","journal-title":"J Pharm Anal."},{"key":"R65-20261114","first-page":"4575","article-title":"A validated HPLC-MS\/MS method for quantification of methotrexate and application for therapeutic drug monitoring in children and adults with non-Hodgkin lymphoma","volume":"2021","author":"Zhichun","year":"2021","journal-title":"Drug Des Devel Ther."},{"key":"R66-20261114","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/FTD.0000000000000515","article-title":"Therapeutic drug monitoring of methotrexate in plasma using ultra high-performance liquid chromatography\u2013electrospray ionization\u2013tandem mass spectrometry: necessary after administration of glucarpidase in methotrexate intoxications","volume":"40","author":"Mulder","year":"2018","journal-title":"Ther Drug Monit."},{"key":"R67-20261114","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.2147\/DDDT.S516431","article-title":"Simultaneous determination of unbound plasma concentration of methotrexate and 7-hydroxymethotrexate in children patients receiving high-dose methotrexate therapy","volume":"19","author":"Dong","year":"2025","journal-title":"Drug Des Devel Ther."},{"key":"R68-20261114","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.2169\/internalmedicine.4999-24","article-title":"Delayed methotrexate elimination following high-dose methotrexate prophylaxis in high-risk diffuse large B-cell lymphoma","volume":"64","author":"Akimoto","year":"2025","journal-title":"Intern Med."},{"key":"R69-20261114","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1002\/cncr.34985","article-title":"A phase 2 study of ibrutinib maintenance following first-line high-dose methotrexate-based chemotherapy for elderly patients with primary central nervous system lymphoma","volume":"129","author":"Bairey","year":"2023","journal-title":"Cancer"},{"key":"R70-20261114","doi-asserted-by":"crossref","first-page":"286","DOI":"10.2152\/jmi.68.286","article-title":"Continued-maintenance therapy with high-dose methotrexate improves overall survival of patients with primary central nervous system lymphoma","volume":"68","author":"Nakajima","year":"2021","journal-title":"J Med Invest."},{"key":"R71-20261114","first-page":"366","article-title":"High-dose methotrexate combined with rituximab improves the survival rate of patients with primary central nervous system lymphoma","volume":"26","author":"Fu","year":"2021","journal-title":"J Buon"},{"key":"R72-20261114","first-page":"vdae119","article-title":"Predicting prognosis outcomes of primary central nervous system lymphoma with high-dose methotrexate-based chemotherapeutic treatment using lipidomics","volume":"6","author":"Zhong","year":"2024","journal-title":"Neurooncol Adv."},{"key":"R73-20261114","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/bjh.15661","article-title":"Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma","volume":"184","author":"Fox","year":"2019","journal-title":"Br J Haematol."},{"key":"R74-20261114","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.6004\/jnccn.2020.7667","article-title":"Challenges in the treatment of newly diagnosed and recurrent primary central nervous system lymphoma","volume":"18","author":"Holdhoff","year":"2020","journal-title":"J Natl Compr Canc Netw."},{"key":"R75-20261114","doi-asserted-by":"crossref","first-page":"825","DOI":"10.14740\/wjon1910","article-title":"Simultaneous determination of methotrexate concentrations in human plasma and cerebrospinal fluid using two-dimensional liquid chromatography: applications in primary central nervous system lymphoma","volume":"15","author":"Wang","year":"2024","journal-title":"World J Oncol."},{"key":"R76-20261114","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13045-022-01356-7","article-title":"Evidence-based expert consensus on the management of primary central nervous system lymphoma in China","volume":"15","author":"Chen","year":"2022","journal-title":"J Hematol Oncol."},{"key":"R77-20261114","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1016\/S2352-3026(15)00074-5","article-title":"Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial","volume":"2","author":"Omuro","year":"2015","journal-title":"Lancet Haematol."},{"key":"R78-20261114","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1177\/10781552221079568","article-title":"Incidence and management of patients with methotrexate delayed elimination in the clinical practice: a Delphi study","volume":"29","author":"Gros","year":"2023","journal-title":"J Oncol Pharm Pract."},{"key":"R79-20261114","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/bcp.16096","article-title":"Navigating methotrexate toxicity: examining the therapeutic roles of folinic acid and glucarpidase","volume":"91","author":"Chan","year":"2025","journal-title":"Br J Clin Pharmacol."},{"key":"R80-20261114","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1111\/bcp.14057","article-title":"Optimising low-dose methotrexate for rheumatoid arthritis-A review","volume":"85","author":"Lucas","year":"2019","journal-title":"Br J Clin Pharmacol."},{"key":"R81-20261114","first-page":"605","article-title":"S2k guideline: diagnosis and therapy of localized scleroderma","volume":"22","author":"Kreuter","year":"2024","journal-title":"J Dtsch Dermatol Ges."},{"key":"R82-20261114","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/jdv.18345","article-title":"European guideline (EuroGuiDerm) on atopic eczema: part I\u2014systemic therapy","volume":"36","author":"Wollenberg","year":"2022","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"R83-20261114","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris\u2014part 1: treatment and monitoring recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"R84-20261114","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1002\/jcph.1837","article-title":"Methotrexate triglutamate as a determinant of clinical response in Mexican patients with rheumatoid arthritis: pharmacokinetics and dose recommendation","volume":"61","author":"Huerta-Garc\u00eda","year":"2021","journal-title":"J Clin Pharmacol."},{"key":"R85-20261114","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1515\/dmpt-2021-0190","article-title":"Factors influencing methotrexate and methotrexate polyglutamate in patients with rheumatoid arthritis: a systematic review of population pharmacokinetics","volume":"37","author":"Methaneethorn","year":"2022","journal-title":"Drug Metab Pers Ther."},{"key":"R86-20261114","first-page":"433","article-title":"Pharmacokinetic monitoring of 24-hour infusion of methotrexate in an adult population with Non-Hodgkin lymphoma [in Spanish]","volume":"28","author":"Fern\u00e1ndez Meg\u00eda","year":"2004","journal-title":"Farm Hosp."},{"key":"R87-20261114","first-page":"371","article-title":"Managing methotrexate toxicity: a case report","volume":"28","author":"Meg\u00eda","year":"2004","journal-title":"Farm Hosp."},{"key":"R88-20261114","first-page":"43","article-title":"Design and validation of a pharmacokinetic model for methotrexate monitoring in hematologic patients","volume":"13","author":"Cantavella","year":"2011","journal-title":"Aten Farm"},{"key":"R89-20261114","first-page":"209","article-title":"Proposal of a model for the monitoring of high-dosage methotrexate in adult patients with acute lymphoblastic leukemia and non-hodgkin's lymphoma","volume":"6","author":"Nicol\u00e1s","year":"2004","journal-title":"Aten Farm"},{"key":"R90-20261114","first-page":"564","article-title":"Blood concentration monitoring during high-dose methotrexate treatment. Article","volume":"31","author":"Jiao","year":"2009","journal-title":"Acta Acad Med Sin"},{"key":"R91-20261114","first-page":"117","article-title":"The effect of MTHFR and ABCB1 genetic polymorphism on serious toxicity and elimination delay of high dose methotrexate","volume":"28","author":"Zhang","year":"2019","journal-title":"Chin J New Drugs."},{"key":"R92-20261114","first-page":"430","article-title":"A retrospective analysis of adverse reactions induced by high-dose methotrexate therapy in hematological malignancies","volume":"70","author":"Osato","year":"2012","journal-title":"J Tokyo Med Univ."},{"key":"R93-20261114","first-page":"133","article-title":"Effect of chai-ling-tang (sairei-to) for methotrexate concentration degradation delay by methotrexate high-dose therapy","volume":"38","author":"Utsuki","year":"2010","journal-title":"Neurol Surg."},{"key":"R94-20261114","first-page":"285","article-title":"Delayed clearance of methotrexate in a patient with malignant lymphoma who developed renal failure","volume":"22","author":"Wakita","year":"1995","journal-title":"JPN J Cancer Chemother."},{"key":"R95-20261114","first-page":"788","article-title":"Inefficacy of exchange-transfusion in a methotrexate intoxication","volume":"84","author":"B\u00e9n\u00e9et","year":"1997","journal-title":"Bull Cancer"},{"key":"R96-20261114","first-page":"760","article-title":"Pharmacokinetik population of methotrexate in Tunisian population with acute lymphoblastic leukemia","volume":"93","author":"Jebabli","year":"2015","journal-title":"Tunis Med."},{"key":"R97-20261114","first-page":"30","article-title":"Treatment of a life-threatening methotrexate intoxication: a case report","volume":"157","author":"Ros","year":"2022","journal-title":"Pharm Weekbl"},{"key":"R98-20261114","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s000630050008","article-title":"Carboxypeptidase-G2 rescue in a patient with MTX-induced renal failure","volume":"95","author":"Von Poblozki","year":"2000","journal-title":"Med Klin"},{"key":"R99-20261114","first-page":"160","article-title":"Problems of high-dose methotrexate in oncological patients","volume":"49","author":"Tav\u010dar","year":"2010","journal-title":"Zdravstveno Varstvo"},{"key":"R100-20261114","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00280-025-04750-3","article-title":"Dose adjustment strategy for high-dose methotrexate-induced toxicities in pediatric acute lymphoblastic leukemia: based on population PK analysis and exposure-toxicity relationship","volume":"95","author":"Cao","year":"2025","journal-title":"Cancer Chemother Pharmacol"},{"key":"R101-20261114","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s40262-024-01452-6","article-title":"Population pharmacokinetic and toxicity analysis of high-dose methotrexate in patients with central nervous system lymphoma","volume":"64","author":"Yin","year":"2025","journal-title":"Clin Pharmacokinet"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001401","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:00:37Z","timestamp":1794664837000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":100,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001401","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"2025-05-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}